

UNITED STATES NUCLEAR REGULATORY COMMISSION WASHINGTON, D.C. 20555-0001

April 3, 2012

Gregory Piefer
Chief Executive Officer
SHINE Medical Technologies, Inc.
8123 Forsythia St., Suite 140
Middleton, WI 53562

Dear Mr. Piefer:

The U.S. Nuclear Regulatory Commission (NRC) is pleased that you will participate in a public Commission meeting on potential medical isotope production licensing actions, on May 11, 2012, at 9:00 a.m. The meeting will be held in the Commissioners' Conference Room on the first floor of the NRC's Headquarters building at One White Flint North, Rockville, Maryland. The Commission is interested in hearing your views, representing SHINE, on SHINE's current status for the production of Mo-99. I am enclosing a copy of the draft meeting agenda for your information (enclosure 1). My staff will keep you informed of any updates to the agenda.

To assist the Commission in preparing for the meeting, please e-mail any written material, including slides/viewgraphs, to Ms. Rochelle Bavol and Ms. Sandy Joosten (rochelle.bavol@nrc.gov and sandy.joosten@nrc.gov) in the Office of the Secretary, by May 4, 2012, so that it can be distributed to the Commission for review in advance of the meeting. Enclosed are guidelines for slides, if you choose to use them (enclosure 2). PowerPoint is the preferred format, but other electronic presentation formats may be used. This Commission meeting will be webcast live at the Web address: www.nrc.gov. If you intend to use slides, they will also be posted on the NRC website prior to the meeting. If you have any questions, please contact Ms. Bavol at 301-415-1651.

Your presentation at the Commission meeting should be based on the assumption that Commissioners are familiar with the content of your written material. Please plan your oral presentation for 10 minutes, discussing the important points on which you wish to focus the Commission's attention.

The NRC Headquarters building is located opposite the White Flint Metro Station on Rockville Pike and Marinelli Drive, Rockville, Maryland. The White Flint Metro Station is on the Red Line of the Washington area subway system. Reserved visitor parking for Commission guests is available. If you wish to use reserved parking, please notify Ms. Bavol in advance. If reserved parking has been arranged, please check-in with the security staff at the entrance to the NRC campus on Marinelli Drive when you arrive. A Security Guard will call for an escort. Please

note that visitors will be screened through metal detectors, will have their packages x-rayed, and will be required to present a picture identification card prior to signing in at the registration desk.

Sincerely,

Andrew L. Bates

Acting Secretary of the Commission

Enclosures:

- 1. Draft Agenda
- 2. Briefing Visuals Guidance

Draft: 4/3/12

SCHEDULING NOTE

Title:

BRIEFING ON POTENTIAL MEDICAL ISOTOPE PRODUCTION

LICENSING ACTIONS (Public)

Purpose:

To provide the Commission with a discussion of the potential for domestic production of the medical isotope molybdenum-99 (Mo-99), including NRC staff's preparations for potential licensing actions and external stakeholders' efforts to establish domestic

production facilities.

Scheduled:

May 11, 2012

9:00 am

Duration:

Approx. 3 hours

Location:

Commissioners' Conference Room OWFN

Participants:

Presentation

External Panel

50 mins.*

Federal Agency Representatives

TBD, Office of Science and Technology (OSTP),

10 mins.*

Executive Office of the President

<u>Topic:</u> OSTP Interagency Working Group overview of efforts to support the domestic production of Mo-99.

Parrish Staples, Director of the Office of European and African Threat

10 mins.*

Reduction, DOE/NNSA

Topic: DOE/NNSA efforts to support the domestic production of Mo-99.

Potential Producer Representatives

Steve Schilthelm, Project Manager, B&W Medical Isotope

10 mins.*

Production System

[Note: B&W has been a recipient of DOE cooperative agreement money since

September 2009.]

Topic: B&W's current status for the production of Mo-99.

Carmen I. Bigles, President and Chief Executive Officer

10 mins.*

Coqui Radiopharmaceuticals Corporation

<u>Topic:</u> Coqui's current status for the production of Mo-99.

Gregory Piefer, Chief Executive Officer SHINE Medical Technologies, Inc.

10 mins.*

Topic: SHINE's current status for the production of Mo-99.

Commission Q & A

50 mins.

Break

5 mins.

NRC Staff Panel

25 mins.*

Bill Borchardt, Executive Director for Operations **Eric Leeds**, Director, NRR **Cathy Haney**, Director, NMSS

Tim McGinty, Director, Division of Policy and Rulemaking, NRR

<u>Topic</u>: Introduction and NRC organizational structure of non-power reactors

Jessie Quichocho, Chief, Research and Reactor Licensing Branch, NRR

<u>Topic:</u> Current status of NRR staffs' efforts for potential medical isotope production licensing actions.

Patricia Silva, Chief, Conversion, Deconversion and Enrichment Branch, NMSS <u>Topic:</u> Current status of NMSS staffs' efforts for potential medical isotope production licensing actions.

Commission Q & A

50 mins.

Discussion - Wrap-up

5 mins.

Documents:

Staff background material due to SECY: April 27, 2012.

Slides due to SECY: May 4, 2012.

^{*}For presentation only and does not include time for Commission Q & A's

PRESENTATION TITLE Arial Black 40 on white background Date of Briefing Your name, title, office Arial Black 32

Slide Title - Arial Black 36

- Text (Arial Black 32) on white.
- Top and Side margins 1 inch min.
- Bottom margin 2 inch min.
- Number pages
- Explain acronyms or include a separate slide with list